Clinical trials: Platelet-aggregation Inhibitors
Cardiovascular Diseases, Acute Coronary Syndrome
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers.
- Trial name
- NCT05474053
- Testing
- Ticagrelor 90mg (Brilique), Ticagrelor 90mg (Ticaloguard)
- Where
- Egypt
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cairo University
Diabetes
Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients
Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D.The aim of the first project is to…
- Trial name
- PANDDA (NCT02302508)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Coronary Artery Disease
Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and Aspirin
This is a randomized, open-label, single-dose, two-sequence, two-period crossover study to investigate the pharmacokinetics between a tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin and the simultaneous…
- Trial name
- NCT01388660
- Testing
- Cloas, Plavix/Astrix
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Acute Coronary Syndrome, Stroke
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008
This is a single-centre, double-blind, randomised, placebo-controlled single oral-dose escalation study in healthy male subjects. It is planned to enrol approximately 48 subjects into up to 6 planned dose level cohorts.
- Trial name
- NCT04770194
- Testing
- SP-8008 Prototype Capsule A, SP-8008 Prototype Capsule B
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Gender, Sex
Sexual Hormones and Haemostasis: Observations for Women Health
Atherothrombotic disorders account for 25% of all deaths among women and for substantial morbidity and resource use in health care.
- Trial name
- SHOW (NCT02055001)
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Analgesia, Obstetrical, Coagulation Defect; Postpartum
IV Ketorolac on Platelet Function Post-Cesarean Delivery
Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption.
- Conditions
- Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage
- Trial name
- KetoPltAgg (NCT03805607)
- Testing
- Ketorolac Tromethamine 30 MG/ML
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Von Willebrand Diseases, Major Constitutional Thrombopathy
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von Willebrand factor, without taking into account blood flow…
- Conditions
- Von Willebrand Diseases, Major Constitutional Thrombopathy, Patient on Antiplatelet Drugs
- Trial name
- INDONESIA (NCT03773159)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Antiplatelet Drug
Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers
This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects.
- Trial name
- NCT04404790
- Testing
- Anfibatide 5 IU/60kg, Anfibatide 5 IU/60kg +0.002 IU/kg/h, Anfibatide 5 IU/60kg +0.004 IU/kg/h
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Platelet Function and Reactivity Tests
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
- Trial name
- NCT06933056
- Testing
- Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Drug Interaction Potentiation, Myocardial Infarction
Drug Drug Interactions of Aspirin and P2Y12-inhibitors
Study Objective: To investigate potential drug-drug interactions (pharmacokinetics and pharmacodynamics) of morphine and antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor)
- Trial name
- NCT01369186
- Testing
- Morphine
- Where
- Austria
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Acute Coronary Syndome
Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?
Background Acute coronary syndrome (ACS) is a term representing all diseases related to reduction in blood flow to the heart characterised by clot formation over a segment of blood vessel narrowing.
- Trial name
- PLATE NOX (NCT02169596)
- Testing
- Ticagrelor, EndoPAT - endothelial assessment
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy…
- Trial name
- NCT04822363
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Blood Platelets, Clopidogrel
PACT (Platelet Activity After Clopidogrel Termination)
Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots. The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after…
- Trial name
- PACT (NCT00619073)
- Testing
- clopidogrel + aspirin, Aspirin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Platelet Aggregation Inhibitors, Aspirin
GM03 - Platelet RNA Signatures of Aspirin
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into…
- Conditions
- Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
- Trial name
- NCT05278637
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Duke University
Healthy
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo…
- Trial name
- CiloMecT (NCT02554721)
- Testing
- Cilostazol, Acetylsalicylic acid, Clopidogrel
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Anticoagulants, Platelet Aggregation Inhibitors
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally…
- Conditions
- Anticoagulants, Platelet Aggregation Inhibitors, Stents, Atrial Fibrillation
- Trial name
- WOEST (NCT00769938)
- Testing
- PCI (percutaneous coronary intervention)
- Where
- 15 sites in Belgium, Netherlands
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- R&D Cardiologie